Victoria Whyte - GlaxoSmithKline plc Insider

GSKN -- Mexico Stock  

MXN 786.85  0.00  0.00%

  Executive
Ms. Victoria L. Whyte serves as Company Secretary of GlaxoSmithKline PLC., since 1 January 2011. She is a solicitor and a Fellow of the Institute of Chartered Secretaries and Administrators. Victoria was formerly Deputy Secretary and Secretary to the Remuneration Committee. She has acted as Secretary to the Board and all the Boards Committees since her appointment as Company Secretary on 1 January 2011.
  Executive Since 2011      
44 20 8047 5000  http://www.gsk.com

Management Efficiency

The company has return on total asset (ROA) of 7.36 % which means that it generated profit of $7.36 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 37.13 % meaning that it generated $37.13 on every $100 dollars invested by stockholders.
The company has accumulated 23.08 B in total debt with debt to equity ratio (D/E) of 486.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. GlaxoSmithKline plc has Current Ratio of 0.6 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Magda CelyEcopetrol S A
2015
Penhung TungAlibaba Group Holding Limited
2016
Margarita EscobarEcopetrol S A
2015
Monica GonzalezEcopetrol S A
2016
Wenhong TongAlibaba Group Holding Limited
2017
Lina ContrerasEcopetrol S A
2016
Chris SuhMicrosoft Corporation
N/A
Jonathan IveApple
N/A
Shan DaiAlibaba Group Holding Limited
2014
Alejandro CantilloEcopetrol S A
2014
Fernan BejaranoEcopetrol S A
N/A
Timothy SteinertAlibaba Group Holding Limited
2007
Xiaofeng ShaoAlibaba Group Holding Limited
2012
Jane JiangAlibaba Group Holding Limited
2016
Ricardo GomezEcopetrol S A
2016
Lei PengAlibaba Group Holding Limited
2014
Zhenfei LiuAlibaba Group Holding Limited
2015
Nancy PaxtonApple
2016
Chenye XuTencent Holdings Limited
2011

Entity Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline plc is traded on Mexico Stock Exchange in Mexico.GlaxoSmithKline plc (GSKN) is traded on Mexico Stock Exchange in Mexico. It is located in 980 Great West Road and employs 98,462 people.

GlaxoSmithKline plc Leadership Team

Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Emma Walmsley, President - Consumer Healthcare Worldwide
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, CEO - GSK Consumer Healthcare
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Non-Executive Director
Bill Louv, Senior Vice President - Core Business Services
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Director
Laurie Glimcher, Non-Executive Director
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Karenann Terrell, Chief Digital & Technology Officer
Claire Thomas, Senior Vice President - Human Resources

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.
Search macroaxis.com